Technology Description
Researchers in Angela Hirbe’s lab at Washington University have developed a method of treating malignant peripheral nerve sheath tumors (MPNSTs) with a combination of inhibitors. The most effective therapy is to combine an inhibitor of TYK2 with a MEK inhibitor.
MPNSTs are often associated with Neurofibromatosis Type 1 or as a secondary complication of radiation therapy. Despite multiple therapeutic options, 50% of patients see a recurrence.
Stage of Research
The researchers have tested the combination of TYK2 and MEK inhibitors on MPNST cells in vitro and on an NF1 model in vivo.
Applications
- Malignant peripheral nerve sheath tumors (MPNSTs)
Key Advantages
- Increases response to MEK inhibitor
Patents: Pending
